S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
MarketBeat Week in Review – 12/4 - 12/8
New CBOE “special perk” helps traders target income every weekend (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
New CBOE “special perk” helps traders target income every weekend (Ad)
What is carbon capture and why does it keep coming up at COP28?
Polish truck drivers are blocking the border with Ukraine. It's hurting on the battlefield
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Dozens of animals taken from Virginia roadside zoo as part of investigation
Peek inside Joe Biden's campaign fundraisers, where big money mingles with old jokes in swanky homes
Top-Rated StocksTop-Rated

Pacira BioSciences (PCRX) Earnings Date, Estimates & Call Transcripts

$28.06
+0.12 (+0.43%)
(As of 12/8/2023 ET)
Compare
Today's Range
$27.62
▼
$28.33
50-Day Range
$26.32
▼
$31.49
52-Week Range
$25.93
▼
$48.60
Volume
229,619 shs
Average Volume
431,939 shs
Market Capitalization
$1.30 billion
P/E Ratio
311.78
Dividend Yield
N/A
Price Target
$52.36
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Feb. 27Estimated
Actual EPS
(Nov. 2)
$0.52 Missed By -$0.13
Consensus EPS
(Nov. 2)
$0.65
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

PCRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PCRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Pacira BioSciences Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20231$0.47$0.47$0.47 
Q2 20232$0.56$0.64$0.60 
Q3 20233$0.76$0.82$0.78 
Q4 20232$1.00$1.08$1.04 
FY 20238$2.79$3.01$2.89 
Q1 20241$0.64$0.64$0.64 
Q2 20241$0.87$0.87$0.87 
Q3 20241$0.95$0.95$0.95 
Q4 20241$0.90$0.90$0.90 
FY 20244$3.36$3.36$3.36 
Q1 20251$0.87$0.87$0.87 
Q2 20251$0.93$0.93$0.93 
Q3 20251$0.93$0.93$0.93 

PCRX Earnings Date and Information

Pacira BioSciences last released its quarterly earnings results on November 2nd, 2023. The reported $0.52 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.65 by $0.13. The business had revenue of $163.93 million for the quarter, compared to the consensus estimate of $172.83 million. Pacira BioSciences has generated $0.09 earnings per share over the last year ($0.09 diluted earnings per share) and currently has a price-to-earnings ratio of 311.8. Earnings for Pacira BioSciences are expected to grow by 33.33% in the coming year, from $2.16 to $2.88 per share. Pacira BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.

Pacira BioSciences Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/27/2024
Estimated)		------- 
11/2/2023Q3 2023$0.65$0.52($0.13)$0.81$172.83 million$163.93 million
8/2/2023Q2 2023$0.59$0.61+$0.02$0.71$175.64 million$169.47 million
5/3/2023Q1 2023$0.40$0.32($0.08)$1.07$157.02 million$160.34 million
2/28/2023Q4 2022$0.71$0.60($0.11)$1.42$174.12 million$171.96 million
11/3/2022Q3 2022$0.40$0.42+$0.02$0.86$167.30 million$167.47 million    
8/3/2022Q2 2022$0.57$0.34($0.23)$0.28$169.27 million$169.41 million      
5/4/2022Q1 2022$0.49$0.45($0.04)$0.75$155.08 million$157.99 million      
2/24/2022Q4 2021$0.60$0.78+$0.18$1.68$157.42 million$159.19 million    
11/2/2021Q3 2021$0.65$0.72+$0.07$0.67$129.69 million$127.70 million    
8/2/2021Q2 2021$0.74$0.77+$0.03$0.78$135.02 million$135.60 million      
5/3/2021Q1 2021$0.64$0.53($0.11)$0.51$119.23 million$119.00 million  
2/24/2021Q4 2020$0.81$0.87+$0.06$0.94$130.91 million$130.90 million  












Pacira BioSciences Earnings - Frequently Asked Questions

When is Pacira BioSciences's earnings date?

Pacira BioSciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off last year's report dates. Learn more on PCRX's earnings history.

Did Pacira BioSciences beat their earnings estimates last quarter?

In the previous quarter, Pacira BioSciences (NASDAQ:PCRX) missed the analysts' consensus estimate of $0.65 by $0.13 with a reported earnings per share (EPS) of $0.52. Learn more on analysts' earnings estimate vs. PCRX's actual earnings.

How much revenue does Pacira BioSciences generate each year?

Pacira BioSciences (NASDAQ:PCRX) has a recorded annual revenue of $666.82 million.

How much profit does Pacira BioSciences generate each year?

Pacira BioSciences (NASDAQ:PCRX) has a recorded net income of $15.91 million. PCRX has generated $0.09 earnings per share over the last four quarters.

What is Pacira BioSciences's price-to-earnings ratio?

Pacira BioSciences (NASDAQ:PCRX) has a trailing price-to-earnings ratio of 311.78 and a forward price-to-earnings ratio of 12.99.

What is Pacira BioSciences's EPS forecast for next year?

Pacira BioSciences's earnings are expected to grow from $2.16 per share to $2.88 per share in the next year, which is a 33.33% increase.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:PCRX) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -